Summary of Medical Surgical Robots Conference Call Industry Overview - The medical surgical robot market in China is in its early stages, with a market size of less than 100 billion RMB, but is experiencing rapid growth due to improvements in policies, payment systems, and hospital demand [1][2][5] - The laparoscopic surgical robot segment is a major focus, with a global market size of approximately 10.2 billion USD and a compound annual growth rate (CAGR) of 17%. The domestic market size is around 4 billion RMB, with a CAGR of 15% [1][3] Key Companies and Market Dynamics - Major players in the laparoscopic surgical robot market include Intuitive Surgical's Da Vinci system, which has a penetration rate in the U.S. of 5,800 units and nearly 10,000 globally, while domestic installations are below 500, indicating significant room for growth [3] - In the orthopedic surgical robot sector, Tianzhihang is a leading domestic company with a high market share, focusing on trauma, spine, and joint surgeries. The market is expected to grow rapidly due to improved policies and clinical demand [1][2][3] Technological Advancements - Significant advancements in surgical robot technology have been made, including breakthroughs in hardware and software systems. The integration of brain-machine interfaces is becoming essential, driving the industry towards high mobility and high-speed automation, significantly enhancing efficiency [4] - The Da Vinci system has achieved a mature status with multi-port and single-port systems, completing over a million cases in the U.S. and achieving a penetration rate of 22% [4] Policy Impact - Recent policy changes have clarified service operation projects and pricing mechanisms, promoting rationalization of service prices and enhancing hospitals' willingness to purchase and use surgical robots. This is expected to accelerate industry development [5] - The payment system is gradually improving, with more hospitals adopting relevant fee structures, which will enhance effective charging capabilities at the terminal level [5] Market Trends and Future Outlook - The demand for surgical robots is strong, particularly for cardiovascular and neurosurgery applications, with companies like Huake Precision capturing significant market shares [8] - Domestic companies are competing with imported brands and are moving towards multi-functional platforms. Tianzhihang has developed a technology platform that covers multiple surgical areas [7] - The overseas market for domestic companies is approaching 10 billion RMB, indicating potential for significant growth in international markets [7] Notable Companies in the Market - Tianzhihang is recognized as a leading orthopedic surgical robot company, with products covering spine, trauma, and joint surgeries, and has received EU CE certification [9][10] - MicroPort Medical is one of the strongest domestic companies, with a product range that includes laparoscopic and orthopedic robots, and has received significant orders [11] - Jingfeng Medical focuses on multi-port and single-port laparoscopic robots, with strong sales performance and a growing presence in international markets [12] - Sanyou Medical is developing a spine surgical robot expected to be launched in 2026, enhancing safety in complex procedures [13] Conclusion - The medical surgical robot industry in China is poised for rapid growth driven by technological advancements, supportive policies, and increasing clinical demand. Domestic companies are making significant strides in both the local and international markets, positioning themselves competitively against established global brands [1][2][5][7][8]

手术机器人：医疗器械黄金赛道，中国企业出海正当时 20260114 摘要 手术机器人市场被认为是医疗器械行业的黄金赛道，预计 2026 年全球 市场规模将达数百亿美元，腔镜机器人占据主要份额，直觉外科收入预 计达上百亿美元。 微创医疗腔镜机器人在中国市场快速发展，截至 2025 年 12 月中旬累 计中标超 160 台，仅 2025 年新增近 120 台，海外市场也呈现爆发式增 长，预计 2025 年订单达 100 台。 精峰医疗已在港股上市，成为中国首家、全球第二家同时获得多孔、单 孔腔镜及自然腔道手术机器人注册的公司，截至 2025 年 6 月已签订 61 台全球销售协议，收入快速增长，海外收入占比 41%。 骨科机器人领域，国内龙头企业如爱康医疗、春立医疗、三友医疗等积 极布局，推出各自产品并处于商业化阶段，预计国内脊柱与关节手术量 将保持稳健增长。 沛嘉医疗预计 2026 年将是发展拐点，神经介入业务已实现扭亏为盈， 瓣膜介入业务受益于价格调整预计手术量增长，反流瓣产品有望带来显 著营收增量。 Q&A 手术机器人行业的商业模式和市场前景如何？ 手术机器人行业的商业模式主要是设备带动耗材的模式，这类似于 ...

Group 1 - The core viewpoint of the article highlights the performance of Huatai Baoxing Health Consumption C and A funds, which experienced declines of 15.23% and 14.71% respectively in 2025 [1][2] - The top ten holdings of the funds are heavily concentrated in the biomedical sector, including companies such as Yuyue Medical, Mindray Medical, United Imaging, Aohua Endoscopy, Nanwei Medical, Anjiesi, Kaili Medical, Huitai Medical, Aibo Medical, and New Industry [1] - The fund manager, Zhao Xuzhao, has a background as a researcher at Guotai Junan Securities and has been with Huatai Baoxing Fund Management since December 2016, managing public funds for over seven years [1] Group 2 - The cumulative unit scale of Huatai Baoxing Health Consumption C is 0.04 billion, and for A it is 0.01 billion, both established on May 27, 2019 [2] - The net value growth rates for Huatai Baoxing Health Consumption C and A are -15.23% and -14.71% respectively, with their net values recorded at 0.9016 and 0.9441 [2]

Core Viewpoint - The medical equipment procurement scale is expected to grow rapidly year-on-year due to the implementation of the 2025 equipment renewal policy, with a significant increase in demand for high-end medical devices [1][2][3] Group 1: Equipment Procurement Trends - In December 2025, the procurement scale for new medical devices showed a decline in MR by 11.8%, CT by 7.3%, DR by 3.9%, and ultrasound by 1.3%, while endoscopes increased by 1.4% and surgical robots decreased by 23.9% [1][2] - Cumulatively for the year 2025, the procurement scale for MR increased by 31.4%, CT by 53.2%, DR by 53.2%, ultrasound by 42.3%, endoscopes by 16.3%, and surgical robots by 21.9% [2] Group 2: Company Performance - In December 2025, the performance of specific companies showed that Union Medical's MR declined by 17.4%, while its CT increased by 17.4%. Mindray's ultrasound grew by 13.8%, and KAILI's ultrasound decreased by 13.5%. KAILI's endoscope increased by 61.1%, and Aohua's endoscope grew by 9.4% [2] - For the entire year of 2025, Union Medical's MR grew by 15.6%, CT by 47.7%, Mindray's ultrasound by 56.3%, KAILI's ultrasound by 69.7%, KAILI's endoscope by 85.0%, and Aohua's endoscope by 24.4% [2] Group 3: Policy Impact - The 2024 policy aims to increase medical equipment investment by over 25% compared to 2023 by 2027, enhancing the configuration of high-end equipment to levels seen in middle-income countries [3] - The implementation of the equipment renewal policy is expected to significantly boost procurement levels across various medical institutions, leading to a recovery in the domestic market and a turning point for equipment companies [3]

Core Viewpoint - The medical equipment bidding scale continues to show good growth, driven by the implementation of equipment renewal policies, which is expected to stimulate long-term procurement levels in the medical equipment sector [1][4]. Group 1: Equipment Renewal Policy Impact - The equipment renewal policy is set to be implemented as planned in 2025, with a rapid year-on-year growth in the annual bidding scale for medical equipment. For instance, in December 2025, the bidding scale for MR decreased by 11.8%, while CT and DR saw declines of 7.3% and 3.9%, respectively. However, the overall annual cumulative growth for 2025 shows significant increases: MR grew by 31.4%, CT by 53.2%, DR by 53.2%, ultrasound by 42.3%, endoscopes by 16.3%, and surgical robots by 21.9% [3][4]. - The four ministries jointly issued a notice in 2024, aiming for a more than 25% increase in medical equipment investment by 2027 compared to 2023, enhancing high-end equipment configurations to levels seen in middle-income countries [4]. Group 2: Market Recovery and Company Performance - The domestic market is showing signs of effective recovery due to policy implementation, with medical equipment companies expected to experience a performance turnaround. For example, in the first three quarters of 2025, United Imaging's domestic revenue reached 6.866 billion yuan, reflecting a year-on-year growth of 23.7%, indicating a recovery and structural upgrade trend in the medical equipment industry [4]. - The demand for innovative diagnostic and treatment equipment, particularly in imaging and radiotherapy, is rapidly increasing as a result of the ongoing equipment renewal policies [4].

（文章来源：证券日报） 证券日报网讯 1月8日，澳华内镜发布公告称，截至2026年1月7日，公司控股股东、实际控制人之一顾 小舟通过集中竞价及大宗交易合计减持260万股，占总股本1.93%，减持金额约1.16亿元，减持计划已实 施完毕，其持股比例降至14.21%。 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2026-002 上海澳华内镜股份有限公司 控股股东、实际控制人减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 控股股东、实际控制人及其一致行动人持有的基本情况 本次减持计划实施前，顾康、顾小舟及其控制的上海小洲光电科技有限公司 （以下简称"小洲光电"）合计持有上海澳华内镜股份有限公司（以下简称"公 司"）40,569,960 股，占公司总股本的 30.13%。其中，小洲光电持有公司股份 1,879,260 股，占公司总股本的 1.40%；顾康持有公司股份 16,950,200 股，占公 司总股本的12.59%；顾小舟持有公司股份21,740,500股，占公司总股本的16.14%。 上述股份来源均为公司首次公开发行前取得的股份，且已于 2024 年 11 月 15 日 起上市流通。 减持计划的实施结果情况 公司于 2025 年 11 月 1 日在上海证券交易所网站（www.sse.com.cn）披露了 《控股股东、实际控制人 ...

澳华内镜公告，控股股东、实际控制人顾小舟已于2025年11月24日至2026年1月7日通过集中竞价减持 134.66万股、大宗交易减持125.34万股，合计减持260万股，减持比例1.93%，减持价格区间41.83～ 47.86元/股，套现1.16亿元；减持计划实施完毕，当前持股1914.05万股，占公司总股本14.21%。 ...

南财智讯1月8日电，澳华内镜公告，公司控股股东、实际控制人之一顾小舟及其一致行动人顾康、小洲 光电本次减持计划已实施完毕。截至2026年1月7日，顾小舟通过集中竞价交易方式累计减持公司股份 1,346,600股，占公司总股本的1.00%；通过大宗交易方式累计减持1,253,400股，占公司总股本的 0.93%，合计减持比例为1.93%。减持价格区间为41.83至47.86元/股，减持总金额为1.16亿元。本次减持 后，顾小舟持股比例由16.14%降至14.21%。 ...

证券时报·数据宝统计显示，澳华内镜今日收盘价为46.48元，上涨2.18%，日换手率为1.98%，成交额为 1.23亿元，全天主力资金净流出623.78万元，近5日该股累计上涨7.10%，近5日资金合计净流入1418.39 万元。 两融数据显示，该股最新融资余额为1.25亿元，近5日增加309.36万元，增幅为2.54%。（数据宝） 1月7日澳华内镜大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | 业部 | | | 62.67 | 2679.77 | 42.76 | -8.00 | 机构专 | 中信证券股份有限公司上海浦东新 | | | | | | 用 | 区联洋证券营业部 | （文章来源：证券时报网） 澳华内镜1月7日大宗交易平台出现一笔成交，成交量62.67万股，成交金额2679.77万元，大宗交易成交 价为42.76元，相对今日收盘价折价8.00%。该笔交易的买方营业部为机构专用，卖方营业部为中信证券 股份有限公司 ...